<sup>18</sup>F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma.

Cancer Imaging · 2019 · PMC6701097 · PMID 31426864

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Both the MGMT promoter methylation status and the radiomics signature stratified the glioma patients into a high-risk group and a low-risk group ( p = 0.0002 and 0.04, respectively), and the differences within the high- and low-risk groups did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.